Lakefront Biotherapeutics

Lakefront Biotherapeutics is a Belgian biotechnology company focused on building and advancing a pipeline in immunology and oncology. The company was formerly known as Galapagos and adopted the Lakefront Biotherapeutics name effective May 8, 2026 as part of a strategic transformation toward a deal-driven, capital-backed model. Its disclosed internal pipeline includes the TYK2 inhibitor GLPG3667 in autoimmune disease and legacy CAR-T programs GLPG5101 and GLPG5301, while a June 2026 transaction with Gilead and Ouro Medicines added access to gamgertamig, a BCMAxCD3 T cell engager for autoimmune diseases. Lakefront emphasizes business development, selective acquisition or in-licensing of clinically validated assets, and disciplined capital allocation. The company is publicly traded and maintains a substantial cash and financial investment base to support additional strategic transactions.